Valneva's Balancing Act: Restructuring Pulls the Reins as Shigella Data Beckons

Valneva cuts 2026 revenue outlook and workforce after Q1 sales drop 40%, while awaiting mid-year Shigella data and Lyme vaccine filing later in 2026.

Valneva is stuck between two narratives. One is the hard arithmetic of a shrinking travel vaccine business, where first-quarter sales slid nearly 40%, forcing management to slash both its outlook and its workforce. The other is the promise of a pipeline that hinges on a mid-year readout for Shigella and a long-anticipated Lyme shot filing later in 2026. For now, the stock is hovering around €2.49, down roughly a percent on the week and 35% since the start of the year, as investors wait to see which story wins.

The numbers from the first quarter left little room for spin. Total revenue fell to €30.9 million from €49.2 million a year earlier, driven by a drop in product sales to €30.5 million from €48.6 million. Valneva blamed weaker demand for travel vaccines in key markets, with IXIARO/JESPECT revenue slipping to €20.2 million from €27.5 million, partly due to the timing of deliveries under the contract with the U.S. Department of Defense. The net loss widened sharply to €32.1 million from €9.2 million, a figure the company attributed to one-off manufacturing costs, contract terminations, inventory write-downs, and the lower top line.

In response, management cut its full-year revenue guidance to a range of €135 million to €150 million, down from the prior band of €145 million to €160 million. To conserve cash, Valneva announced a restructuring that will trim 10% to 15% of its global headcount, with operating expenses targeted to fall 25% to 35% below last year's level. The liquidity picture is not dire — cash stood at €105.3 million at the end of March, little changed from €109.7 million in December — and a reserved placement added €37 million in gross proceeds. Operating cash burn shrank to just €0.3 million from €8.1 million. Still, the margin for error has narrowed, and the success of the cost-cutting program is now central to financial stability.

On the pipeline front, the next major catalyst is the Phase 2 data for S4V2, Valneva's tetravalent Shigella vaccine candidate, expected in mid-2026. Two studies are under way: one testing safety and immunogenicity in infants, and a Phase 2b human challenge trial assessing protection. Both are sponsored by LimmaTech Biologics AG. If results are positive, Valneva will take over further development. The FDA granted S4V2 fast-track status in October 2024, and Valneva sees a global market potential of more than $500 million annually for a Shigella vaccine, an area with no approved multivalent shot outside Russia and China. Separately, the Lyme vaccine program — developed with Pfizer — remains on track for FDA and EMA submissions in the second half of 2026, with the partners citing positive efficacy and safety data from the VALOR trial.

Analyst sentiment is deeply divided. Goldman Sachs downgraded the stock to Sell and cut its price target from €3.25 to €2.15, pointing to multiple setbacks including the Ixchiq withdrawal and the missed VALOR endpoint. On the other side, Jefferies maintains a target of $15.00, and Guggenheim holds a Buy rating with an $11.00 target, arguing that Pfizer's involvement in the Lyme program and the residual regulatory value of the pipeline are being underappreciated.

The technical picture offers little comfort. The 50-, 100-, and 200-day moving averages all sit well above the current price, and the Relative Strength Index at 51 signals neither oversold strength nor momentum. Resistance is pegged at €2.74, a level the stock has not reclaimed since its slide, while support near €2.25 corresponds to the May 4 low. A break above resistance would offer the first credible hint of a trend change. Until then, the shares are caught between the drag of a lowered forecast and the hope of a pipeline that has yet to deliver its next proof point. The half-year report will be the next scheduled opportunity to shift the narrative.